AC Immune SA
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving AC Immune SA now
Current reporting with the operating signal separated from the noise.
AC Immune SA IMR
The story matters when it changes AC Immune SA’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.AC Immune SA (ACIU) Stock Price, News, Quote & History
Investors are testing whether AC Immune SA’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.AC Immune Says Investigational Parkinson’s Drug Shows 100% Antibody Response
The story matters when it changes AC Immune SA’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.AC Immune SA Reports Positive Safety And Immunogenicity Results Through Week-100 In Part 1 Of VacSYn Phase 2 Trial Of ACI-7104
The story matters when it changes AC Immune SA’s customers, execution, competitive position or capital requirements.
Watch next: regulator filings, verified operating scope and liability disclosures.AC Immune SA to Highlight Advanced Immunotherapy Pipeline at AD/PD™ 2025 Conference
The story matters when it changes AC Immune SA’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.AC IMMUNE SA Earnings Results: $ACIU Reports Quarterly Earnings
Investors are testing whether AC Immune SA’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.AC Immune SA Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Investors are testing whether AC Immune SA’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.AC Immune SA (NASDAQ:ACIU) stock most popular amongst individual investors who own 32%, while private equity firms hold 29%
Investors are testing whether AC Immune SA’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.AC Immune SA
The story matters when it changes AC Immune SA’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest ACIU filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
AC Immune SA, quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →